A Phase 2 interventional study of Hydrocortisone Modified Release Capsules in Endocrine Disease, Adrenal Insufficiency and Congenital Adrenal Hyperplasia, sponsored by Neurocrine UK Limited. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Neurocrine UK Limited (formerly part of Neurocrine Biosciences) · Phase 2, Interventional, and Treatment
The purpose of this study is to gather safety and effectiveness information about a new formulation of Hydrocortisone (Chronocort®) used to treat patients with a disease called congenital adrenal hyperplasia (CAH). Hydrocortisone is the man-made version of the hormone cortisol, which is released in the body following a regular daily pattern. The objective of the study is to measure the levels of hydrocortisone that are absorbed into the bloodstream once Chronocort® is taken and what affects it has on other hormones in the body. Since Chronocort® is anticipated to mimic the same release pattern of cortisol in the body, it is hoped that patients with CAH will be treated more effectively to manage their disease.
This study is a Phase 2 pilot study to characterize and examine the pharmacokinetics and efficacy profile of Chronocort® in adults with congenital adrenal hyperplasia (CAH). It is designed as a two-part, single cohort, open label, multiple dose Phase 2 pilot study to: (Part A) characterize and examine the pharmacokinetics (PK) and disease bio-marker behavior following short-term dosing with Chronocort®; and to (Part B) examine the disease control after six months dose titration with Chronocort® in adults with CAH.
322 studies on the registry are indexed under Endocrine System Diseases; 51 are open to participants now.
This study's enrollment of 16 is below the median of 69 across 221 interventional studies indexed under Endocrine System Diseases.
Browse Endocrine System Diseases studies →Neurocrine UK Limited is the lead sponsor of 18 studies on the registry; none are open to participants now.
First submitted before Neurocrine UK Limited left Neurocrine Biosciences.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
Drug: Hydrocortisone Modified Release Capsules
Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment
Also known as: Chronocort
Pharmacokinetic Profile (Cmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia
The maximum plasma concentration (Cmax) of chronocort
Time frame: 24 hours
Pharmacokinetic Profile (AUC0-24) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia
Area under the curve (AUC) from 0 to 24 hours (sampling occurs at the following timepoints: 2300, 0100, 0300, 0500, 0600, 0700, 0800, 0900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1900, 2100, 2300hrs)
Time frame: 24 hours (at 2300, 0100, 0300, 0500, 0600, 0700, 0800, 0900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1900, 2100, 2300hrs)
Pharmacokinetic Profile (Tmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia
Time to maximum plasma concentration (tmax)
Time frame: 24 hours
The Percentage of Patients With 17-OHP and Androstenedione Levels at 0700h Within Proposed Optimal Ranges Whilst on Chronocort and Whilst on Standard Therapy (at Baseline)
Proposed optimal ranges of 17-OHP: 300-1200ng/dl Proposed optimal ranges of androstenedione: 40-150ng.dl for males and 30-200ng/dl for females
Time frame: Specific time point (0700hrs)
17-OHP Levels at 0700h, 1700h and 2300h
17-OHP levels at 0700h, 1700h and 2300h
Time frame: Specified time points (0700h, 1700h and 2300h)
Androstenedione Levels at 0700h, 1700h and 2300h
Androstenedione levels at 0700h, 1700h and 2300h
Time frame: Specified time points (0700h, 1700h and 2300h)
ACTH Levels at 0700h, 1700h and 2300h
ACTH levels at 0700h, 1700h and 2300h
Time frame: Specified time points (0700h, 1700h and 2300h)
AUC Values (Nmol*h/L) for Androstenedione
AUC values (nmol\*h/L) for Androstenedione for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h
Time frame: Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h)
AUC Values (Nmol*h/L) for 17-OHP
AUC values (nmol\*h/L) for 17-OHP for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h
Time frame: Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h)
AUC Values (Pmol*h/L) for ACTH
AUC values (pmol\*h/L) for ACTH for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h
Time frame: Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h)
| Milestone | Hydrocortisone Modified Release Capsules |
|---|---|
| Started | 16 |
| Completed | 16 |
| Not completed | 0 |
The maximum plasma concentration (Cmax) of chronocort
| nmol/L | Chronocort |
|---|---|
| Pharmacokinetic Profile (Cmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia | 601.213 ± 114.5987 |
Area under the curve (AUC) from 0 to 24 hours (sampling occurs at the following timepoints: 2300, 0100, 0300, 0500, 0600, 0700, 0800, 0900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1900, 2100, 2300hrs)
| h*nmol/L | Chroncort |
|---|---|
| Pharmacokinetic Profile (AUC0-24) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia | 5027.641 ± 1247.8425 |
Time to maximum plasma concentration (tmax)
| Hours | Chronocort |
|---|---|
| Pharmacokinetic Profile (Tmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia | 7.9 ± 2.9 |
Proposed optimal ranges of 17-OHP: 300-1200ng/dl Proposed optimal ranges of androstenedione: 40-150ng.dl for males and 30-200ng/dl for females
| percentage of participants | Hydrocortisone Modified Release Capsules |
|---|---|
| 17-OHP (baseline) | 0 |
| 17-OHP (final visit) | 12.5 |
| Androstenedione (baseline) | 56.3 |
| Androstenedione (final visit) | 81.3 |
17-OHP levels at 0700h, 1700h and 2300h
| nmol/L | Hydrocortisone Modified Release Capsules |
|---|---|
| 17-OHP: Part A, Days 1-2 (0700h) | 76.97 ± 91.986 |
| 17-OHP: Part A, Days 1-2 (1700h) | 70.99 ± 104.106 |
| 17-OHP: Part A, Days 1-2 (2300h) | 55.35 ± 93.632 |
| 17-OHP: Part A, Days 4-5 (0700h) | 7.72 ± 8.231 |
| 17-OHP: Part A, Days 4-5 (1700h) | 23.55 ± 66.046 |
| 17-OHP: Part A, Days 4-5 (2300h) | 27.27 ± 55.140 |
| 17-OHP: Part B, Visit 2 (0700h) | 24.86 ± 54.086 |
| 17-OHP: Part B, Visit 2 (1700h) | 15.17 ± 20.400 |
| 17-OHP: Part B, Visit 2 (2300h) | 26.65 ± 51.185 |
| 17-OHP: Part B, Visit 3 (0700h) | 34.87 ± 49.072 |
| 17-OHP: Part B, Visit 3 (1700h) | 13.81 ± 20.700 |
| 17-OHP: Part B, Visit 3 (2300h) | 18.95 ± 28.276 |
| 17-OHP: Part B, Visit 4 (0700h) | 13.67 ± 19.091 |
| 17-OHP: Part B, Visit 4 (1700h) | 34.70 ± 69.876 |
| 17-OHP: Part B, Visit 4 (2300h) | 22.19 ± 46.826 |
Androstenedione levels at 0700h, 1700h and 2300h
| nmol/L | Hydrocortisone Modified Release Capsules |
|---|---|
| Androstenedione: Part A, Days 1-2 (0700h) | 7.92 ± 8.474 |
| Androstenedione: Part A, Days 1-2 (1700h) | 7.54 ± 7.966 |
| Androstenedione: Part A, Days 1-2 (2300h) | 7.43 ± 9.388 |
| Androstenedione: Part A, Days 4-5 (0700h) | 3.11 ± 2.178 |
| Androstenedione: Part A, Days 4-5 (1700h) | 4.62 ± 8.005 |
| Androstenedione: Part A, Days 4-5 (2300h) | 5.37 ± 8.340 |
| Androstenedione: Part B, Visit 2 (0700h) | 4.96 ± 6.731 |
| Androstenedione: Part B, Visit 2 (1700h) | 3.47 ± 3.094 |
| Androstenedione: Part B, Visit 2 (2300h) | 3.79 ± 3.748 |
| Androstenedione: Part B, Visit 3 (0700h) | 4.57 ± 3.561 |
| Androstenedione: Part B, Visit 3 (1700h) | 3.61 ± 2.713 |
| Androstenedione: Part B, Visit 3 (2300h) | 3.91 ± 3.103 |
| Androstenedione: Part B, Visit 4 (0700h) | 3.40 ± 1.973 |
| Androstenedione: Part B, Visit 4 (1700h) | 4.19 ± 4.602 |
| Androstenedione: Part B, Visit 4 (2300h) | 3.37 ± 2.655 |
ACTH levels at 0700h, 1700h and 2300h
| pmol/L | Hydrocortisone Modified Release Capsules |
|---|---|
| ACTH: Part A, Days 1-2 (0700h) | 21.06 ± 29.767 |
| ACTH: Part A, Days 1-2 (1700h) | 20.93 ± 30.121 |
| ACTH: Part A, Days 1-2 (2300h) | 7.75 ± 9.873 |
| ACTH: Part A, Days 4-5 (0700h) | 4.16 ± 9.190 |
| ACTH: Part A, Days 4-5 (1700h) | 4.71 ± 7.382 |
| ACTH: Part A, Days 4-5 (2300h) | 7.37 ± 7.990 |
| ACTH: Part B, Visit 2 (0700h) | 7.02 ± 12.159 |
| ACTH: Part B, Visit 2 (1700h) | 5.57 ± 6.769 |
| ACTH: Part B, Visit 2 (2300h) | 8.66 ± 14.637 |
| ACTH: Part B, Visit 3 (0700h) | 9.66 ± 12.418 |
| ACTH: Part B, Visit 3 (1700h) | 4.71 ± 6.331 |
| ACTH: Part B, Visit 3 (2300h) | 6.04 ± 7.997 |
| ACTH: Part B, Visit 4 (0700h) | 12.18 ± 29.911 |
| ACTH: Part B, Visit 4 (1700h) | 13.66 ± 22.851 |
| ACTH: Part B, Visit 4 (2300h) | 9.44 ± 17.474 |
AUC values (nmol\*h/L) for Androstenedione for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h
| nmol*h/L | Hydrocortisone Modified Release Capsules |
|---|---|
| Androstenedione: Part A, Days 1-2 AUC (2300-2300h) | 166.19 ± 171.969 |
| Androstenedione: Part A, Days 1-2 AUC (2300-0700h) | 41.42 ± 34.133 |
| Androstenedione: Part A, Days 1-2 AUC (0700-1500h) | 65.33 ± 76.337 |
| Androstenedione: Part A, Days 1-2 AUC (1500-2300h) | 59.44 ± 65.995 |
| Androstenedione: Part A, Days 4-5 AUC (2300-2300h) | 104.37 ± 128.725 |
| Androstenedione: Part A, Days 4-5 AUC (2300-0700h) | 36.02 ± 40.225 |
| Androstenedione: Part A, Days 4-5 AUC (0700-1500h) | 32.01 ± 31.503 |
| Androstenedione: Part A, Days 4-5 AUC (1500-2300h) | 37.91 ± 58.394 |
| Androstenedione: Part B, Visit 2 AUC (2300-2300h) | 88.58 ± 86.364 |
| Androstenedione: Part B, Visit 2 AUC (2300-0700h) | 35.12 ± 43.580 |
| Androstenedione: Part B, Visit 2 AUC (0700-1500h) | 26.07 ± 22.298 |
| Androstenedione: Part B, Visit 2 AUC (1500-2300h) | 27.39 ± 23.989 |
| Androstenedione: Part B, Visit 3 AUC (2300-2300h) | 91.46 ± 65.295 |
| Androstenedione: Part B, Visit 3 AUC (2300-0700h) | 33.25 ± 26.255 |
| Androstenedione: Part B, Visit 3 AUC (0700-1500h) | 27.92 ± 16.297 |
| Androstenedione: Part B, Visit 3 AUC (1500-2300h) | 30.30 ± 26.188 |
| Androstenedione: Part B, Visit 4 AUC (2300-2300h) | 86.27 ± 70.892 |
| Androstenedione: Part B, Visit 4 AUC (2300-0700h) | 29.09 ± 23.314 |
| Androstenedione: Part B, Visit 4 AUC (0700-1500h) | 27.03 ± 20.009 |
| Androstenedione: Part B, Visit 4 AUC (1500-2300h) | 30.13 ± 28.797 |
AUC values (nmol\*h/L) for 17-OHP for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h
| nmol*h/L | Hydrocortisone Modified Release Capsules |
|---|---|
| 17-OHP: Part A, Days 1-2 AUC 2300-2300h | 1407.83 ± 1829.291 |
| 17-OHP: Part A, Days 1-2 AUC 2300-0700h | 243.99 ± 339.580 |
| 17-OHP: Part A, Days 1-2 AUC 0700-1500h | 607.74 ± 805.822 |
| 17-OHP: Part A, Days 1-2 AUC 1500-2300h | 556.11 ± 769.492 |
| 17-OHP: Part A, Days 4-5 AUC 2300-2300h | 446.90 ± 817.074 |
| 17-OHP: Part A, Days 4-5 AUC 2300-0700h | 169.83 ± 268.178 |
| 17-OHP: Part A, Days 4-5 AUC 0700-1500h | 91.53 ± 147.801 |
| 17-OHP: Part A, Days 4-5 AUC 1500-2300h | 190.73 ± 425.505 |
| 17-OHP: Part B, Visit 2 AUC 2300-2300h | 395.65 ± 587.533 |
| 17-OHP: Part B, Visit 2 AUC 2300-0700h | 168.01 ± 337.666 |
| 17-OHP: Part B, Visit 2 AUC 0700-1500h | 82.41 ± 91.708 |
| 17-OHP: Part B, Visit 2 AUC 1500-2300h | 145.24 ± 215.115 |
| 17-OHP: Part B, Visit 3 AUC 2300-2300h | 432.02 ± 393.897 |
| 17-OHP: Part B, Visit 3 AUC 2300-0700h | 152.63 ± 144.576 |
| 17-OHP: Part B, Visit 3 AUC 0700-1500h | 139.21 ± 147.353 |
| 17-OHP: Part B, Visit 3 AUC 1500-2300h | 140.18 ± 182.786 |
| 17-OHP: Part B, Visit 4 AUC 2300-2300h | 436.54 ± 678.052 |
| 17-OHP: Part B, Visit 4 AUC 2300-0700h | 101.33 ± 148.003 |
| 17-OHP: Part B, Visit 4 AUC 0700-1500h | 120.32 ± 172.134 |
| 17-OHP: Part B, Visit 4 AUC 1500-2300h | 214.89 ± 364.641 |
AUC values (pmol\*h/L) for ACTH for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h
| pmol*h/L | Hydrocortisone Modified Release Capsules |
|---|---|
| ACTH: Part A, Days 1-2 AUC (2300-2300h) | 356.25 ± 415.949 |
| ACTH: Part A, Days 1-2 AUC (2300-0700h) | 54.72 ± 70.267 |
| ACTH: Part A, Days 1-2 AUC (0700-1500h) | 166.18 ± 206.294 |
| ACTH: Part A, Days 1-2 AUC (1500-2300h) | 135.35 ± 169.002 |
| ACTH: Part A, Days 4-5 AUC (2300-2300h) | 120.00 ± 121.454 |
| ACTH: Part A, Days 4-5 AUC (2300-0700h) | 52.22 ± 62.067 |
| ACTH: Part A, Days 4-5 AUC (0700-1500h) | 21.29 ± 19.824 |
| ACTH: Part A, Days 4-5 AUC (1500-2300h) | 47.13 ± 57.145 |
| ACTH: Part B, Visit 2 AUC (2300-2300h) | 125.45 ± 118.081 |
| ACTH: Part B, Visit 2 AUC (2300-0700h) | 43.09 ± 46.711 |
| ACTH: Part B, Visit 2 AUC (0700-1500h) | 34.14 ± 48.423 |
| ACTH: Part B, Visit 2 AUC (1500-2300h) | 48.22 ± 49.078 |
| ACTH: Part B, Visit 3 AUC (2300-2300h) | 154.10 ± 172.474 |
| ACTH: Part B, Visit 3 AUC (2300-0700h) | 50.02 ± 57.268 |
| ACTH: Part B, Visit 3 AUC (0700-1500h) | 52.46 ± 64.571 |
| ACTH: Part B, Visit 3 AUC (1500-2300h) | 51.63 ± 70.735 |
| ACTH: Part B, Visit 4 AUC (2300-2300h) | 252.30 ± 420.220 |
| ACTH: Part B, Visit 4 AUC (2300-0700h) | 58.80 ± 107.955 |
| ACTH: Part B, Visit 4 AUC (0700-1500h) | 110.58 ± 329.386 |
| ACTH: Part B, Visit 4 AUC (1500-2300h) | 82.92 ± 120.287 |
Collected over Approximately 7 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hydrocortisone Modified Release Capsules | — | 0/16 (0%) | 16/16 (100%) |
| Event | Hydrocortisone Modified Release Capsules |
|---|---|
| HeadacheNervous system disorders | 13/16 |
| FatigueGeneral disorders | 13/16 |
| DizzinessNervous system disorders | 8/16 |
| AnaemiaBlood and lymphatic system disorders | 7/16 |
| Weight increaseInvestigations | 7/16 |
| Appetite decreaseMetabolism and nutrition disorders | 7/16 |
| Appetite increaseMetabolism and nutrition disorders | 6/16 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/16 |
| InsomniaPsychiatric disorders | 5/16 |
| AcneSkin and subcutaneous tissue disorders | 5/16 |
All treated subjects
| Age, Continuous(years) | Hydrocortisone Modified Release Capsules |
|---|---|
| Mean | 28.7 ± 12.97 |
| Sex: Female, Male(Participants) | Hydrocortisone Modified Release Capsules |
|---|---|
| Female | 8 |
| Male | 8 |
| Race (NIH/OMB)(Participants) | Hydrocortisone Modified Release Capsules |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 13 |
| More than one race | 1 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Hydrocortisone Modified Release Capsules |
|---|---|
| United States | 16 |
Plan to share: No
The record gives a start of Dec 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2017, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hydrocortisone